|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: METTL17 |
Gene summary for METTL17 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | METTL17 | Gene ID | 64745 |
| Gene name | methyltransferase like 17 | |
| Gene Alias | METT11D1 | |
| Cytomap | 14q11.2 | |
| Gene Type | protein-coding | GO ID | GO:0006412 | UniProtAcc | Q9H7H0 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 64745 | METTL17 | LZE2T | Human | Esophagus | ESCC | 2.91e-02 | 5.29e-01 | 0.082 |
| 64745 | METTL17 | LZE4T | Human | Esophagus | ESCC | 2.28e-15 | 3.43e-01 | 0.0811 |
| 64745 | METTL17 | LZE5T | Human | Esophagus | ESCC | 9.74e-03 | 1.29e-01 | 0.0514 |
| 64745 | METTL17 | LZE7T | Human | Esophagus | ESCC | 4.32e-14 | 3.69e-01 | 0.0667 |
| 64745 | METTL17 | LZE8T | Human | Esophagus | ESCC | 2.04e-09 | 2.44e-01 | 0.067 |
| 64745 | METTL17 | LZE20T | Human | Esophagus | ESCC | 2.23e-04 | 1.89e-01 | 0.0662 |
| 64745 | METTL17 | LZE24T | Human | Esophagus | ESCC | 6.90e-16 | 4.38e-01 | 0.0596 |
| 64745 | METTL17 | P1T-E | Human | Esophagus | ESCC | 3.65e-09 | 3.41e-01 | 0.0875 |
| 64745 | METTL17 | P2T-E | Human | Esophagus | ESCC | 1.12e-28 | 4.52e-01 | 0.1177 |
| 64745 | METTL17 | P4T-E | Human | Esophagus | ESCC | 4.21e-27 | 5.82e-01 | 0.1323 |
| 64745 | METTL17 | P5T-E | Human | Esophagus | ESCC | 3.19e-21 | 3.42e-01 | 0.1327 |
| 64745 | METTL17 | P8T-E | Human | Esophagus | ESCC | 2.03e-32 | 5.24e-01 | 0.0889 |
| 64745 | METTL17 | P9T-E | Human | Esophagus | ESCC | 7.50e-19 | 2.56e-01 | 0.1131 |
| 64745 | METTL17 | P10T-E | Human | Esophagus | ESCC | 3.43e-52 | 7.68e-01 | 0.116 |
| 64745 | METTL17 | P11T-E | Human | Esophagus | ESCC | 3.30e-10 | 5.51e-01 | 0.1426 |
| 64745 | METTL17 | P12T-E | Human | Esophagus | ESCC | 1.58e-64 | 1.14e+00 | 0.1122 |
| 64745 | METTL17 | P15T-E | Human | Esophagus | ESCC | 4.35e-42 | 8.71e-01 | 0.1149 |
| 64745 | METTL17 | P16T-E | Human | Esophagus | ESCC | 4.11e-33 | 4.91e-01 | 0.1153 |
| 64745 | METTL17 | P17T-E | Human | Esophagus | ESCC | 3.30e-04 | 2.78e-01 | 0.1278 |
| 64745 | METTL17 | P19T-E | Human | Esophagus | ESCC | 1.14e-02 | 2.53e-01 | 0.1662 |
| Page: 1 2 3 4 5 6 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma | ||
| Thyroid |  | ATC: Anaplastic thyroid cancer |
| HT: Hashimoto's thyroiditis | ||
| PTC: Papillary thyroid cancer |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:0022613111 | Esophagus | ESCC | ribonucleoprotein complex biogenesis | 365/8552 | 463/18723 | 1.74e-49 | 1.11e-45 | 365 |
| GO:0042254111 | Esophagus | ESCC | ribosome biogenesis | 252/8552 | 299/18723 | 3.27e-44 | 1.04e-40 | 252 |
| GO:0042274111 | Esophagus | ESCC | ribosomal small subunit biogenesis | 67/8552 | 73/18723 | 6.62e-17 | 5.38e-15 | 67 |
| GO:00322592 | Esophagus | ESCC | methylation | 222/8552 | 364/18723 | 2.26e-09 | 5.09e-08 | 222 |
| GO:002261322 | Liver | HCC | ribonucleoprotein complex biogenesis | 355/7958 | 463/18723 | 7.76e-52 | 4.92e-48 | 355 |
| GO:004225422 | Liver | HCC | ribosome biogenesis | 246/7958 | 299/18723 | 4.99e-46 | 1.58e-42 | 246 |
| GO:004227422 | Liver | HCC | ribosomal small subunit biogenesis | 65/7958 | 73/18723 | 1.09e-16 | 9.92e-15 | 65 |
| GO:0032259 | Liver | HCC | methylation | 206/7958 | 364/18723 | 3.35e-08 | 7.53e-07 | 206 |
| GO:002261320 | Oral cavity | OSCC | ribonucleoprotein complex biogenesis | 333/7305 | 463/18723 | 8.28e-48 | 5.24e-44 | 333 |
| GO:004225420 | Oral cavity | OSCC | ribosome biogenesis | 230/7305 | 299/18723 | 3.22e-41 | 6.80e-38 | 230 |
| GO:004227420 | Oral cavity | OSCC | ribosomal small subunit biogenesis | 63/7305 | 73/18723 | 7.61e-17 | 6.34e-15 | 63 |
| GO:00322591 | Oral cavity | OSCC | methylation | 168/7305 | 364/18723 | 3.03e-03 | 1.31e-02 | 168 |
| GO:0022613110 | Oral cavity | LP | ribonucleoprotein complex biogenesis | 259/4623 | 463/18723 | 7.20e-48 | 2.25e-44 | 259 |
| GO:0042254110 | Oral cavity | LP | ribosome biogenesis | 173/4623 | 299/18723 | 8.97e-35 | 1.41e-31 | 173 |
| GO:0042274110 | Oral cavity | LP | ribosomal small subunit biogenesis | 48/4623 | 73/18723 | 1.42e-13 | 1.35e-11 | 48 |
| GO:0022613113 | Thyroid | PTC | ribonucleoprotein complex biogenesis | 292/5968 | 463/18723 | 3.24e-44 | 2.05e-40 | 292 |
| GO:0042254113 | Thyroid | PTC | ribosome biogenesis | 202/5968 | 299/18723 | 3.47e-37 | 5.47e-34 | 202 |
| GO:0042274113 | Thyroid | PTC | ribosomal small subunit biogenesis | 54/5968 | 73/18723 | 1.77e-13 | 9.28e-12 | 54 |
| GO:00322594 | Thyroid | PTC | methylation | 146/5968 | 364/18723 | 4.99e-04 | 3.26e-03 | 146 |
| GO:002261334 | Thyroid | ATC | ribonucleoprotein complex biogenesis | 292/6293 | 463/18723 | 3.05e-39 | 9.63e-36 | 292 |
| Page: 1 2 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| METTL17 | SNV | Missense_Mutation | rs758787257 | c.454N>A | p.Glu152Lys | p.E152K | Q9H7H0 | protein_coding | tolerated(0.17) | probably_damaging(0.981) | TCGA-AR-A0TX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| METTL17 | SNV | Missense_Mutation | c.835G>A | p.Glu279Lys | p.E279K | Q9H7H0 | protein_coding | tolerated(0.17) | benign(0.044) | TCGA-BH-A18P-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | PD | |
| METTL17 | SNV | Missense_Mutation | c.835G>C | p.Glu279Gln | p.E279Q | Q9H7H0 | protein_coding | tolerated(0.11) | benign(0.44) | TCGA-GM-A2D9-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD | |
| METTL17 | insertion | Frame_Shift_Ins | novel | c.54_55insATAAATTTCCTACAAGGAATCATTTCACAAA | p.Gly19IlefsTer31 | p.G19Ifs*31 | Q9H7H0 | protein_coding | TCGA-BH-A0AY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | SD | |||
| METTL17 | deletion | Frame_Shift_Del | novel | c.795delN | p.Ser267ProfsTer2 | p.S267Pfs*2 | Q9H7H0 | protein_coding | TCGA-EW-A2FV-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | docetaxel | SD | ||
| METTL17 | SNV | Missense_Mutation | rs758407608 | c.1055C>T | p.Ala352Val | p.A352V | Q9H7H0 | protein_coding | tolerated(0.18) | benign(0.088) | TCGA-EA-A3HU-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | SD |
| METTL17 | SNV | Missense_Mutation | novel | c.778N>C | p.Asp260His | p.D260H | Q9H7H0 | protein_coding | deleterious(0) | probably_damaging(0.975) | TCGA-VS-A8EL-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
| METTL17 | SNV | Missense_Mutation | c.695N>G | p.Lys232Arg | p.K232R | Q9H7H0 | protein_coding | tolerated(0.29) | benign(0.13) | TCGA-A6-2686-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| METTL17 | SNV | Missense_Mutation | c.1004A>G | p.His335Arg | p.H335R | Q9H7H0 | protein_coding | deleterious(0.02) | probably_damaging(0.999) | TCGA-AA-3710-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | |
| METTL17 | SNV | Missense_Mutation | rs772938639 | c.1189N>T | p.Arg397Cys | p.R397C | Q9H7H0 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 5 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |